WHO Pharmaceuticals Newsletter 2003, No. 04
(2003; 13 pages) Voir le document au format PDF
Table des matières
Ouvrir ce répertoire et afficher son contenuREGULATORY MATTERS
Fermer ce répertoireSAFETY OF MEDICINES
Afficher le documentATYPICAL ANTI-PSYCHOTICS - Reports of hypertension
Afficher le documentBOTULINUM A - Patients misled over safety
Afficher le documentCHELIDONIUM MAJUS - Statement to advise use under supervision
Afficher le documentCYCLO-OXYGENASE (COX)-2 INHIBITORS - Reports of hepatotoxicity
Afficher le documentETONOGESTREL - Vaginal bleeding with sub-dermal implant
Afficher le documentFLUTICASONE - ADR update
Afficher le documentGATIFLOXACIN - Reports of abnormal glucose metabolism
Afficher le documentHORMONE REPLACEMENT THERAPY (HRT) - ‘Million Women Study’ confirms breast cancer association
Afficher le documentMEDROXY-PROGESTERONE - Reports of contraception failure with depot preparations
Afficher le documentMEFLOQUINE - Patient guide warns of psychiatric adverse events
Afficher le documentMETHOTREXATE - New solutions to prevent fatalities/adverse events
Afficher le documentMINOCYCLINE - Hepatic reactions
Afficher le documentPIPERACILLIN - Serum methotrexate monitoring advised during concomitant therapy
Afficher le documentRIFAMPICIN & PYRAZINAMIDE - Warning against use in latent tuberculosis
Afficher le documentSELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs): Reports of hyponatraemia
Afficher le documentSIBUTRAMINE - Serotonin syndrome
Afficher le documentTICLOPIDINE - No decrease in ADR reports
Afficher le documentVIGA/VIGA FOR WOMEN - Presence of sildenafil
Afficher le documentWARFARIN & MICONAZOLE - Reminder about interaction
Ouvrir ce répertoire et afficher son contenuDRUGS IN THE NEWS
 

MINOCYCLINE - Hepatic reactions

Australia. The Adverse Drug Reactions Advisory Committee (ADRAC) in Australia has received 42 reports of hepatic reactions, including 21 of hepatitis, associated with minocycline; in most cases minocycline was the sole suspected drug. In 28 cases minocycline was being used to treat acne and 15 of the 42 patients were less than 21 years old. Of the 42 cases, 25 had recovered by the time of reporting, most within 12 weeks of stopping minocycline; none of the patients died or required liver transplantation. The Committee notes that five cases were suggestive of an autoimmune reaction, with antinuclear antibodies and, in one case, features of lupus erythematosus. Prescribers are advised that hepatitis in a patient receiving long-term minocycline may be indistinguishable from auto-immune hepatitis; however, discontinuation of minocycline usually results in complete recovery.

Reports in WHO-file: Liver and biliary system disorders 600

Reference:

Adverse Drug Reactions Advisory Committee (ADRAC). Hepatic reactions with minocycline.
Australian Adverse Drug Reactions Bulletin 22: 11, Jun 2003.

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 3 mai 2013